Back to Bills
HOUSE-BILL 6321119th Congress

HOUSE-BILL 6321: H.R.6321 - Lung Cancer Medicare Access to Precise Testing Act

Introduced: November 28, 2025
Status: Referred to Committee
supported

AI-Powered Summary

Generated by AI Analysis

HOUSE-BILL 6321 aims to enhance access to lung cancer biomarker testing for Medicare beneficiaries, reflecting a commitment to personalized medicine and improved health outcomes for individuals diagnosed with lung cancer. The bill addresses major themes of health care access and government regulation of health services, mandating that Medicare cover these critical diagnostic tests at 100% of reasonable charges, thereby removing financial barriers for patients. Key provisions include a clear definition of lung cancer biomarker testing based on individual biological samples, ensuring tailored medical care. The implementation of this coverage is set for January 1, 2027, providing a timeline for necessary adjustments within the Medicare system. Potential impacts include improved health care access for lung cancer patients, but there may be constitutional concerns regarding the extent of government involvement in health care and equal protection issues if certain groups are disproportionately affected by the coverage requirements.

Demographic Impact Analysis

AI Demographics Analysis

Summary

Overall Constitutional Implications

The bill supports the provision of necessary medical services, particularly for vulnerable populations such as seniors and individuals with disabilities. By mandating Medicare coverage for lung cancer biomarker testing, it aims to improve health outcomes and access to care.

Key Individual Rights Affected

  • Right to Health Care
  • Equal Protection under the Law

Constitutional Provisions

  • 14th Amendment - Equal Protection Clause
  • Social Security Act - Federal Powers

Potential Constitutional Challenges Or Support

Support

The bill promotes public health and welfare, which is a legitimate government interest.

Concerns

If the implementation leads to disparities in access based on demographic characteristics, it could raise equal protection issues.

Summary

HOUSE-BILL 6321 aims to improve access to lung cancer biomarker testing, which is crucial for effective treatment. While it generally supports constitutional principles by enhancing health care access, careful implementation is necessary to ensure that it does not create disparities among different demographic groups, thereby upholding the Equal Protection Clause.

Constitutional Analysis

supported

This bill appears to align with constitutional principles. The proposed legislation operates within the established framework of constitutional authority and does not appear to conflict with fundamental rights or the separation of powers.

Analysis generated using AI-powered review of constitutional principles and legal precedents.

Take Action

Text 50409

💡 How to use:

These links will start a conversation with ResistBot. When prompted, mention H.R. 6321 to reference this bill.

Contact Your Representatives

Write to YOUR elected officials about this bill

Rate This Bill

Sign in to save a private rating for this bill and track your civic engagement over time.

Sign In Free

Policy Topics

Timeline

November 28, 2025

Bill Introduced

Current

Referred to Committee

June 12, 2026

Last Updated

Ask the Constitutional AI About This Bill

Sign in free to chat with our constitutional analysis AI about this bill — get plain-English explanations, constitutional concerns, and demographic impact estimates personalized to you.

Sign In Free to Chat